Long-term follow-up for multiple sclerosis patients initially treated with interferon-beta and glatiramer acetate

被引:7
作者
Healy, Brian C. [1 ,2 ,3 ]
Glanz, Bonnie I. [1 ,2 ]
Zurawski, Jonathan D. [1 ,2 ]
Mazzola, Maria [1 ,2 ]
Chitnis, Tanuja [1 ,2 ]
Weiner, Howard L. [1 ,2 ]
机构
[1] Brigham & Womens Hosp, Partners Multiple Sclerosis Ctr, 75 Francis St, Boston, MA 02115 USA
[2] Harvard Med Sch, Dept Neurol, Boston, MA USA
[3] Massachusetts Gen Hosp, Biostat Ctr, Boston, MA 02114 USA
关键词
Multiple sclerosis; Treatment; Long term outcomes; PLACEBO-CONTROLLED TRIAL; RELAPSE RATE; DOUBLE-BLIND; DISABILITY; PROGRESSION; DISEASE;
D O I
10.1016/j.jns.2018.09.020
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: Our goal was to compare subjects treated with glatiramer acetate (GA) and interferon-beta (IFN-13) in terms of long-term clinical outcomes. Methods: Subjects enrolled in the CLIMB who initiated either GA or IFN-13 within five years of disease onset and prior to 2008 were identified (n = 150 for GA and n = 144 for IFN-13). The two treatment groups were compared in terms of long-term clinical outcomes: time to EDSS 4, time to EDSS 6 and EDSS score seven years after treatment initiation. Baseline confounders included in our analysis were age, gender, disease duration, attacks in the previous year, EDSS prior to treatment initiation, and year of treatment initiation. The groups were compared using three approaches to handle confounders: multiple regression adjusting for confounders, adjustment for the propensity score, and inverse probability of treatment weighting. In addition, we assessed potential predictors of differential treatment response using multiple regression models including appropriate interaction terms. Results: Subjects initially treated with GA had a slightly higher hazard of reaching EDSS 4 and EDSS 6, but the difference between the groups was not statistically significant (adjusted HR for EDSS 4 = 1.48; 95% CI: 0.77,2.84; p =.24; adjusted HR for EDSS 6 = 1.46; 95% CI: 0.70,3.05; p =.316). For the EDSS score at year 7, there was also only a small difference between the groups. Subjects treated with GA had a longer time until treatment cessation (adjusted HR = 0.70; 95% CI: 0.53,0.93; p =.012). The interaction models did not show strong evidence for the baseline predictors being associated with treatment response. Conclusions: Subjects treated with glatiramer acetate and interferon-beta had similar long-term clinical course.
引用
收藏
页码:127 / 131
页数:5
相关论文
共 50 条
[41]   Clean intermittent catheterization in multiple sclerosis patients: An adherence and long-term follow-up study [J].
Maillard, Berengere ;
Cassol, Helena ;
Slomian, Justine ;
Bornheim, Stephen ;
Kaux, Jean-Francois ;
Waltregny, David ;
Keppenne, Veronique .
FRENCH JOURNAL OF UROLOGY, 2024, 34 (13)
[42]   Non-adherence to interferon-beta therapy in Swedish patients with multiple sclerosis [J].
Cunningham, A. ;
Gottberg, K. ;
von Koch, L. ;
Hillert, J. .
ACTA NEUROLOGICA SCANDINAVICA, 2010, 121 (03) :154-160
[43]   Different clinical response to interferon beta and glatiramer acetate related to the presence of oligoclonal IgM bands in CSF in multiple sclerosis patients [J].
Casanova, Bonaventura ;
Lacruz, Laura ;
Villar, Maria Luisa ;
Dominguez, Jose Andres ;
Gadea, Maria Carcelen ;
Gascon, Francisco ;
Mallada, Javier ;
Hervas, David ;
Simo-Castello, Maria ;
Alvarez-Cermeno, Jose Carlos ;
Calles, Carmen ;
Olascoaga, Javier ;
Ramio-Torrenta, Lluis ;
Alcala, Carmen ;
Cervello, Angeles ;
Bosca, Isabel ;
Perez-Mirallles, Francisco Carlos ;
Coret, Francisco .
NEUROLOGICAL SCIENCES, 2018, 39 (08) :1423-1430
[44]   Baseline Gene Expression Signatures in Monocytes from Multiple Sclerosis Patients Treated with Interferon-beta [J].
Bustamante, Marta F. ;
Nurtdinov, Ramil N. ;
Rio, Jordi ;
Montalban, Xavier ;
Comabella, Manuel .
PLOS ONE, 2013, 8 (04)
[45]   Long-term treatment of multiple sclerosis with glatiramer acetate: Natural history of the subtypes of anti-glatiramer acetate antibodies and their correlation with clinical efficacy [J].
Karussis, Dimitros ;
Teitelbaum, Dvora ;
Sicsic, Camille ;
Brenner, Talma .
JOURNAL OF NEUROIMMUNOLOGY, 2010, 220 (1-2) :125-130
[46]   Interferon-beta therapy in multiple sclerosis: the short-term and long-term effects on the patients’ individual gene expression in peripheral blood [J].
Michael Hecker ;
Christiane Hartmann ;
Ole Kandulski ;
Brigitte Katrin Paap ;
Dirk Koczan ;
Hans-Juergen Thiesen ;
Uwe Klaus Zettl .
Molecular Neurobiology, 2013, 48 :737-756
[47]   Interferon-beta therapy in multiple sclerosis: the short-term and long-term effects on the patients' individual gene expression in peripheral blood [J].
Hecker, Michael ;
Hartmann, Christiane ;
Kandulski, Ole ;
Paap, Brigitte Katrin ;
Koczan, Dirk ;
Thiesen, Hans-Juergen ;
Zettl, Uwe Klaus .
MOLECULAR NEUROBIOLOGY, 2013, 48 (03) :737-756
[48]   Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis [J].
He, Anna ;
Spelman, Tim ;
Jokubaitis, Vilija ;
Havrdova, Eva ;
Horakova, Dana ;
Trojano, Maria ;
Lugaresi, Alessandra ;
Izquierdo, Guillermo ;
Grammond, Pierre ;
Duquette, Pierre ;
Girard, Marc ;
Pucci, Eugenio ;
Iuliano, Gerardo ;
Alroughani, Raed ;
Oreja-Guevara, Celia ;
Fernandez-Bolanos, Ricardo ;
Grand'Maison, Francois ;
Sola, Patrizia ;
Spitaleri, Daniele ;
Granella, Franco ;
Terzi, Murat ;
Lechner-Scott, Jeannette ;
Van Pesch, Vincent ;
Hupperts, Raymond ;
Luis Sanchez-Menoyo, Jose ;
Hodgkinson, Suzanne ;
Rozsa, Csilla ;
Verheul, Freek ;
Butzkueven, Helmut ;
Kalincik, Tomas .
JAMA NEUROLOGY, 2015, 72 (04) :405-413
[49]   A comparison of the mechanisms of action of interferon beta and glatiramer acetate in the treatment of multiple sclerosis [J].
Zhang, JW ;
Hutton, G ;
Zang, Y .
CLINICAL THERAPEUTICS, 2002, 24 (12) :1998-2021
[50]   Differential Transcription of SOCS5 and SOCS7 in Multiple Sclerosis Patients Treated with Interferon Beta or Glatiramer Acetate [J].
Rojas-Morales, Emmanuel ;
Santos-Lopez, Gerardo ;
Hernandez-Cabanas, Samuel ;
Arcega-Revilla, Raul ;
Rosas-Murrieta, Nora ;
Jasso-Miranda, Carolina ;
El-Kassis, Elie Girgis ;
Reyes-Leyva, Julio ;
Sedeno-Monge, Virginia .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (01)